Efficacy and safety of nintedanib (N) versus sorafenib (S) in Caucasian and Asian patients with advanced hepatocellular carcinoma (HCC): Pooled analysis of two randomized phase II trials.

被引：0
|
作者：
Meyer, Tim
Palmer, Daniel H.
Chao, Yee
Choi, Caren
Deptala, Andrzej
Fartoux, Laetitia
Feng, Yin-Hsun
Graham, Janet Shirley
Hocke, Julia
Kim, Tae-You
Lin, Deng-Yn
Ma, Yuk Ting
Peck-Radosavljevic, Markus
Ross, Paul J.
Ryoo, Baek-Yeol
Wenz, Arne
Yen, Chia-Jui
Loembe, Arsene-Bienvenu
Cheng, Ann-Lii
机构：
[1] UCL, Inst Canc, London, England
[2] Univ Liverpool, Canc Res UK Ctr, Liverpool L69 3BX, Merseyside, England
[3] Taipei Vet Gen Hosp, Taipei, Taiwan
[4] Boehringer Ingelheim Korea, Seoul, South Korea
[5] Minist Interior, Cent Clin Hosp, Dept Hematol & Oncol, Warsaw, Poland
[6] Med Univ Warsaw, Warsaw, Poland
[7] Hop St Antoine, F-75571 Paris, France
[8] Chi Mei Med Ctr Yongkang, Tainan, Taiwan
[9] Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland
[10] Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany
[11] Seoul Natl Univ, Coll Med, Seoul Natl Univ Hosp, Dept Internal Med,Canc Res Inst, Seoul, South Korea
[12] Chang Gung Mem Hosp, Guishan, Taiwan
[13] Chang Gung Univ, Coll Med, Guishan, Taiwan
[14] Univ Birmingham, Sch Canc Sci, Birmingham, W Midlands, England
[15] Med Univ Wien, Dept Gastroenterol & Hepatol, Vienna, Austria
[16] Kings Coll Hosp NHS Fdn Trust, London, England
[17] Asan Med Ctr, Seoul, South Korea
[18] Natl Cheng Kung Univ Hosp, Tainan 70428, Taiwan
[19] Boehringer Ingelheim BV, Alkmaar, Netherlands
[20] Natl Taiwan Univ Hosp, Taipei, Taiwan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.4074
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4074
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Combined analysis of two randomised Phase II trials comparing the efficacy and safety of nintedanib versus sorafenib in Caucasian and Asian patients with advanced hepatocellular carcinoma
    Palmer, D.
    Meyer, T.
    Chao, Y.
    Deptala, A.
    Fartoux, L.
    Feng, Y. -H.
    Graham, J.
    Lin, D. -Y.
    Ma, Y. T.
    Peck-Radosavljevic, M.
    Ross, P.
    Ryoo, B. -Y.
    Yen, C. -J.
    Hocke, J.
    Vlassak, S.
    Wenz, A.
    Loembe, A. -B.
    Cheng, A. -L.
    [J]. ANNALS OF ONCOLOGY, 2015, 26
  • [2] Efficacy and safety of nintedanib versus sorafenib in Asian patients with advanced hepatocellular carcinoma (HCC): A randomized phase II trial.
    Cheng, Ann-Lii
    Yen, Chia-Jui
    Kim, Tae-You
    Feng, Yin-Hsun
    Chao, Yee
    Lin, Deng-Yn
    Loembe, Arsene-Bienvenu
    Hocke, Julia
    Choi, Caren
    Ryoo, Baek-Yeol
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [3] Randomized phase II trial comparing the efficacy and safety of nintedanib versus sorafenib in patients with advanced hepatocellular carcinoma (HCC)
    Palmer, Daniel H.
    Ma, Yuk Ting
    Peck-Radosavljevic, Markus
    Ross, Paul J.
    Graham, Janet Shirley
    Fartoux, Laetitia
    Deptala, Andrzej
    Wenz, Arne
    Hocke, Julia
    Loembe, Arsene-Bienvenu
    Meyer, Tim
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [4] Efficacy and safety of nintedanib vs sorafenib in Asian patients with advanced hepatocellular carcinoma (HCC): A randomised Phase II trial
    Yen, C.
    Kim, T. Y.
    Feng, Y. H.
    Chao, Y.
    Lin, D. Y.
    Studeny, M.
    Hocke, J.
    Huang, D. C. L.
    Ryoo, B. Y.
    Cheng, A. L.
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 : S612 - S612
  • [5] A Phase I/Randomized Phase II Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Nintedanib versus Sorafenib in Asian Patients with Advanced Hepatocellular Carcinoma
    Yen, Chia-Jui
    Kim, Tae-You
    Feng, Yin-Hsun
    Chao, Yee
    Lin, Deng-Yn
    Ryoo, Baek-Yeol
    Huang, Dennis Chin-Lun
    Schnell, David
    Hocke, Julia
    Loembe, Arsene-Bienvenu
    Cheng, Ann-Lii
    [J]. LIVER CANCER, 2018, 7 (02) : 165 - 178
  • [6] mRECIST to predict survival in advanced hepatocellular carcinoma: Analysis of two randomized phase II trials comparing nintedanib versus sorafenib
    Meyer, Tim
    Palmer, Daniel H.
    Cheng, Ann-Lii
    Hocke, Julia
    Loembe, Arsene-Bienvenu
    Yen, Chia-jui
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [7] Randomized phase III trial of sorafenib versus placebo in patients with advanced hepatocellular carcinoma (HCC)
    Llovet, J.
    Ricci, S.
    Mazzaferro, V.
    Hilgard, P.
    Raoul, J.
    Zeuzem, S.
    Poulin-Costello, M.
    Moscovici, M.
    Voliotis, D.
    Bruix, J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [8] Phase II trial of tepotinib vs sorafenib in Asian patients (pts) with advanced hepatocellular carcinoma (HCC)
    Ryoo, B-Y.
    Ren, Z.
    Kim, T-Y.
    Pan, H.
    Rau, K-M.
    Choi, H. J.
    Park, J-W.
    Kim, J. H.
    Yen, C-J.
    Kim, B-H.
    Zhou, D.
    Straub, J.
    Zhao, C.
    Qin, S.
    [J]. ANNALS OF ONCOLOGY, 2018, 29
  • [9] mRECIST to predict survival in advanced hepatocellular carcinoma: Analysis of two randomised phase II trials comparing nintedanib vs sorafenib
    Meyer, Tim
    Palmer, Daniel H.
    Cheng, Ann-Lii
    Hocke, Julia
    Loembe, Arsene-Bienvenu
    Yen, Chia-Jui
    [J]. LIVER INTERNATIONAL, 2017, 37 (07) : 1047 - 1055
  • [10] Open-label, phase I/randomized, phase II trial of the triple angiokinase inhibitor, nintedanib, versus sorafenib in previously untreated patients with advanced hepatocellular carcinoma (HCC)
    Palmer, Daniel H.
    Peck-Radosavljevic, Markus
    Ma, Yuk Ting
    Graham, Janet
    Fartoux, Laetitia
    Hubner, Richard
    Loembe, Arsene Bienvenu
    Studeny, Matus
    Hocke, Julia
    Meyer, Tim
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345